We spoke with CRI Lloyd J. Old STAR Dr. Peter E. Fecci of Duke University about his work in removing barriers to immunotherapy against tumors within the intracranial compartment. #immunotherapy #BrainCancer [ Ссылка ]
Brain cancer is notoriously resistant to current immunotherapies, partially due to the “immune privilege” granted by the blood-brain barrier, but perhaps even more so due to unique tumor mircoenvironments that can hinder immune responses.
To address this, Dr. Fecci is examining how brain tumors, and the intracranial environment in general, promote T cell dysfunction and prevent effective immunity. Specifically, he seeks to systematically categorize tumor-induced immune dysfunction, as well as understand the role of tumor heterogeneity in hindering immunotherapy responses.
By uncovering ways to subvert the tumor-induced immunologic vacuum into which therapies—including both checkpoint immunotherapies and CAR T cells—are delivered, he hopes to discover insights into how we might improve immune cell access and anti-cancer activity within the brain. Ultimately, he hopes to translate this knowledge of tumor immune evasion mechanisms into the design of novel, rational, and successful cancer immunotherapies.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. [ Ссылка ]
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
